Publications by authors named "Victor Cervera-Carrascon"

Claim this Profile
S
Single-cell profiling of peripheral blood mononuclear cells from patients treated with oncolytic adenovirus TILT-123 reveals baseline immune status as a predictor of therapy outcomes.
Tatiana V Kudling, Dmitrii Bychkov, James H A Clubb, Santeri A Pakola, Victor Arias, Victor Cervera-Carrascon

Cancer Gene Ther· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oncolytic adenoviruses in platinum-resistant ovarian cancer: a new era in immunotherapy?
Santeri Artturi Pakola, James Hugo Armstrong Clubb, Joao Manuel Santos, Riikka Havunen, Heini Lassus, Victor Cervera-Carrascon

Expert Opin Biol Ther· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oncolytic adenovirus encoding variant interleukin-2 combined with chemotherapy enables PD-L1 inhibition in pancreatic cancer models.
Santeri A Pakola, Nea Ojala, Tatiana V Kudling, James H A Clubb, Elise Jirovec, Victor Cervera-Carrascon

Cancer Immunol Immunother· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Boosting anti-tumor immunity with TILT-517 oncolytic adenovirus and checkpoint blockade in renal cell carcinoma.
Victor Arias, Tatiana V Kudling, James H A Clubb, Elise Jirovec, Santeri A Pakola, Victor Cervera-Carrascon

Mol Ther Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus TILT-123 in metastatic melanoma.
Tine J Monberg, Santeri A Pakola, Benedetta Albieri, Eva Ellebaek, Marco Donia, Victor Cervera-Carrascon

Cell Rep Med· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The oncolytic adenovirus TILT-123 with pembrolizumab in platinum resistant or refractory ovarian cancer: the phase 1a PROTA trial.
Matthew Stephen Block, James Hugo Armstrong Clubb, Johanna Mäenpää, Santeri Pakola, Dafne Carolina Alves Quixabeira, Víctor Cervera-Carrascon

Nat Commun· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transient lymphocyte count decrease correlates with oncolytic adenovirus efficacy in humans: mechanistic and biomarker findings from TUNIMO phase I trial.
Santeri A Pakola, James H A Clubb, Tatiana V Kudling, Mirte van der Heijden, Elise Jirovec, Victor Cervera-Carrascon

J Immunother Cancer· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single intravenous administration of oncolytic adenovirus TILT-123 results in systemic tumor transduction and immune response in patients with advanced solid tumors.
Elise Jirovec, Dafne C A Quixabeira, James H A Clubb, Santeri A Pakola, Tatiana Kudling, Victor Cervera-Carrascon

J Exp Clin Cancer Res· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, Efficacy, and Biological Data of T-Cell-Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I Trial.
Santeri A Pakola, Katriina J Peltola, James H A Clubb, Elise Jirovec, Lyna Haybout, Victor Cervera-Carrascon

Clin Cancer Res· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overcoming effector T cell exhaustion in ovarian cancer ascites with a novel adenovirus encoding for a MUC1 bispecific antibody engager and IL-2 cytokine.
Saru Basnet, Mirte Van der Heijden, Dafne C A Quixabeira, Elise Jirovec, Susanna A M Grönberg-Vähä-Koskela, Victor Cervera-Carrascon

Mol Ther· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overcoming effector T cell exhaustion in ovarian cancer ascites with a novel adenovirus encoding for a MUC1 bispecific antibody engager and IL-2 cytokine.
Saru Basnet, Mirte Van der Heijden, Dafne C A Quixabeira, Elise Jirovec, Susanna A M Grönberg-Vähä-Koskela, Victor Cervera-Carrascon

Mol Ther· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effective intravenous delivery of adenovirus armed with TNFα and IL-2 improves anti-PD-1 checkpoint blockade in non-small cell lung cancer.
Tatiana V Kudling, James H A Clubb, Santeri Pakola, Dafne C A Quixabeira, Iris A K Lähdeniemi, Victor Cervera-Carrascon

Oncoimmunology· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An oncolytic adenovirus coding for a variant interleukin 2 cytokine improves response to chemotherapy through enhancement of effector lymphocyte cytotoxicity, fibroblast compartment modulation and mitotic slippage.
Santeri Pakola, Dafne C A Quixabeira, Tatiana V Kudling, James H A Clubb, Susanna Grönberg-Vähä-Koskela, Victor Cervera-Carrascon

Front Immunol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oncolytic adenovirus coding for bispecific T cell engager against human MUC-1 potentiates T cell response against solid tumors.
Saru Basnet, Joao M Santos, Dafne C A Quixabeira, James H A Clubb, Susanna A M Grönberg-Vähä-Koskela, Victor Cervera-Carrascon

Mol Ther Oncolytics· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a Syrian hamster anti-PD-L1 monoclonal antibody enables oncolytic adenoviral immunotherapy modelling in an immunocompetent virus replication permissive setting.
James H A Clubb, Tatiana V Kudling, Mykhailo Girych, Lyna Haybout, Santeri Pakola, Víctor Cervera-Carrascon

Front Immunol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effective Combination Immunotherapy with Oncolytic Adenovirus and Anti-PD-1 for Treatment of Human and Murine Ovarian Cancers.
Camilla Heiniö, James Clubb, Tatiana Kudling, Dafne Quixabeira, Victor Cervera-Carrascon

Diseases· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Local delivery of interleukin 7 with an oncolytic adenovirus activates tumor-infiltrating lymphocytes and causes tumor regression.
Tatiana V Kudling, James H A Clubb, Dafne C A Quixabeira, Joao M Santos, Riikka Havunen, Victor Cervera-Carrascon

Oncoimmunology· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Local therapy with an engineered oncolytic adenovirus enables antitumor response in non-injected melanoma tumors in mice treated with aPD-1.
Dafne C A Quixabeira, Victor Cervera-Carrascon, Joao M Santos, James H A Clubb, Tatiana V Kudling

Oncoimmunology· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adenovirus Encoding Tumor Necrosis Factor Alpha and Interleukin 2 Induces a Tertiary Lymphoid Structure Signature in Immune Checkpoint Inhibitor Refractory Head and Neck Cancer.
James H A Clubb, Tatiana V Kudling, Camilla Heiniö, Saru Basnet, Santeri Pakola

Front Immunol· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adenovirus Armed With TNFa and IL2 Added to aPD-1 Regimen Mediates Antitumor Efficacy in Tumors Refractory to aPD-1.
Victor Cervera-Carrascon, Dafne C A Quixabeira, Joao M Santos, Riikka Havunen, Ioanna Milenova

Front Immunol· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oncolytic Adenovirus Coding for a Variant Interleukin 2 (vIL-2) Cytokine Re-Programs the Tumor Microenvironment and Confers Enhanced Tumor Control.
Dafne C A Quixabeira, Sadia Zafar, Joao M Santos, Victor Cervera-Carrascon, Riikka Havunen

Front Immunol· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhanced Stability and Bioactivity of Natural Anticancer Topoisomerase I Inhibitors through Cyclodextrin Complexation.
Víctor González-Ruiz, Ángel Cores, Olmo Martín-Cámara, Karen Orellana, Víctor Cervera-Carrascón

Pharmaceutics· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systemic Delivery of Oncolytic Adenovirus to Tumors Using Tumor-Infiltrating Lymphocytes as Carriers.
Joao Santos, Camilla Heiniö, Dafne Quixabeira, Sadia Zafar, James Clubb, Victor Cervera-Carrascon

Cells· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oncolytic Adenovirus ORCA-010 Activates Proinflammatory Myeloid Cells and Facilitates T Cell Recruitment and Activation by PD-1 Blockade in Melanoma.
Ioanna Milenova, Marta Lopez Gonzalez, Dafne C A Quixabeira, Joao Manuel Santos, Victor Cervera-Carrascon

Hum Gene Ther· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cytokine-Coding Oncolytic Adenovirus TILT-123 Is Safe, Selective, and Effective as a Single Agent and in Combination with Immune Checkpoint Inhibitor Anti-PD-1.
Riikka Havunen, Riikka Kalliokoski, Mikko Siurala, Suvi Sorsa, João M Santos, Victor Cervera-Carrascon

Cells· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis